We are pleased to announce that Werlabs is now listed for trading on Eqvor's platform.
Werlabs is a Swedish health technology company focused on data-driven preventive care. The company combines medical quality, digital distribution and scalable technology in an offering aimed at both private individuals and employers. The company was founded in 2013 and is a registered care provider with IVO (the Swedish Health and Social Care Inspectorate).
Through blood tests, health questionnaires and doctor's analysis, users get structured follow-up of their health over time. According to the company, millions of biomarkers have been analysed and over 350,000 individuals have received support in interpreting their health data.experience of building digital service companies in regulated environments.
Product and technology
The core offering consists of blood-based health checks in which test results are presented in a digital record together with a doctor's assessment and recommendations. Werlabs works with accredited laboratories such as Karolinska University Laboratory, Unilabs and Synlab. The company has also developed more advanced health measures, including Biological Age, and is investing in AI support for clinical interpretation. A collaboration with Intel has been announced within AI-based decision support for preventive medicine.experience of building digital service companies in regulated environments.
Growth and focus
Werlabs has grown in step with increased interest in preventive health. During the pandemic, the company quickly shifted capacity towards large-scale COVID-related services (testing and later vaccination), which brought a clear breakthrough in volume and revenue.
Since the pandemic period, the company has clearly refocused on its core business: health checks and data-driven health monitoring for private individuals and companies, with continued emphasis on medical quality, user experience and scalability. In parallel, over the past two years the company has invested significant amounts in its own technical platform and infrastructure. These investments are now largely complete, which is expected to contribute to improved margins from 2026 as the cost base stabilises and economies of scale are realised.
The underlying business is growing again, with around 2% organic growth YTD as of Q3. The result for Q3 2025 YTD amounts to -6.8 MSEK at EBIT level, with around 10 MSEK in platform and growth investments weighing on the result. Adjusted for these investments, operational profitability appears significantly stronger.
Owners and management
Werlabs' shareholder base includes well-known Swedish entrepreneurs and investors, including Philian (Karl-Johan Persson), Cristina Stenbeck, Jonas Nordlander and Filip Engelbert. Management has solid experience of building digital service companies in regulated environments, and signals a long-term approach.
Werlabs operates at the intersection of medical quality, data-driven analysis and digital distribution – an area characterised by long-term structural growth drivers. With an established business, a clear focus on preventive health and a scalable business model, the company offers interesting exposure to health technology with both commercial and societal relevance.
You can find more information about the Werlabs share HERE.
